infuse Life Science, Inc., a pioneering research-driven startup focused on revolutionizing the life sciences for the Ob-GYN healthcare industry, today announced that it has been selected as a finalist of the Tokyo SME grant. This grant will support the development of the company's second product, which follows its previously Tokyo SME grant-selected diagnostic method.

The selection is an important step to the company's commitment to innovation and its strong track record in research and development. This latest product, combined with our existing diagnostic solution, will enable us to offer a comprehensive suite of products to address unmet needs in the life sciences field.

“This notification of grant approval is a testament to the broader understanding of our vision beyond a single product, but as a comprehensive solution,” said Dai Saito, CEO of infuse Life Science, Inc. “We are committed to working diligently to bring these products to clinical implementation as soon as possible.”